BIO-RAD LABORATORIES, INC. - Class B Common Stock (BIO)

Historical Holders from Q1 2014 to Q3 2025

Symbol: BIO on NYSE
Type / Class: Equity / Class B Common Stock
Shares outstanding: 5.07M
All holders as of 30 Sep 2025: Q3 2025
Total 13F shares, excl. options: 19.5M
Holdings value: $5.46B
% of all portfolios: 0.01%
Grand Portfolio weight change: +0%
Number of holders: 384
Number of buys: 176
Number of sells: -185
Average Value change %: +0%
Average buys %: +0.002%
Average sells %: -0.002%

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Significant Owners of BIO-RAD LABORATORIES, INC. - Class B Common Stock (BIO)

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
SCHWARTZ NORMAN D	97.2%		$1.38B		4.93M		Norman D. Schwartz	25 Sep 2025
SCHWARTZ ALICE N	12.3%		$659M		2.73M		Alice N. Schwartz	01 May 2025
First Eagle Investment Management, LLC	11.4%	+14%	$657M	$60.8M	2.53M	+10.2%	First Eagle Investment Management, LLC	30 Jun 2025
VANGUARD GROUP INC	8.37%		$463M		1.91M		The Vanguard Group - 23-1945930	30 Sep 2024
BlackRock, Inc.	7.4%		$454M		1.62M		BlackRock, Inc.	30 Sep 2025

Institutional Holders of BIO-RAD LABORATORIES, INC. - Class B Common Stock (BIO)

Period	Reported Shares, Excl. Options	Value, Excl. Options	Change	Puts Notional Value	Calls Notional Value	Price	Investors
2025 Q3	19.5M	$5.46B	+$100M	925K	1.68M	$280.39	384
2025 Q2	19.2M	$4.63B	+$3.47M	8.57M	2.58M	$241.32	380
2025 Q1	19.2M	$4.67B	+$53M	3.51M	3.09M	$243.56	429
2024 Q4	18.8M	$6.17B	-$216M	3.78M	5.16M	$328.51	450
2024 Q3	19.4M	$6.48B	-$219M	4.65M	6.52M	$334.58	433
2024 Q2	19.8M	$5.41B	+$314M	10.2M	6.34M	$273.11	428
2024 Q1	18.5M	$6.39B	+$32.7M	27.6M	15.5M	$345.87	456
2023 Q4	18.5M	$5.98B	-$116M	26.8M	45.2M	$322.89	479
2023 Q3	18.8M	$6.73B	-$58.7M	23.4M	21.5M	$358.45	466
2023 Q2	18.3M	$6.94B	-$192M	39.3M	22.6M	$379.12	463
2023 Q1	19.2M	$9.2B	+$12.1M	35.7M	37M	$479.02	499
2022 Q4	19.3M	$8.11B	-$118M	62.8M	43.5M	$420.49	467
2022 Q3	19.5M	$8.14B	+$114M	87.6M	75.6M	$417.14	471
2022 Q2	19.1M	$9.46B	+$34.5M	93M	32M	$495.00	489
2022 Q1	19.2M	$10.8B	-$34.4M	83.3M	57M	$563.23	505
2021 Q4	19.1M	$14.4B	-$390M	97.1M	41M	$755.57	521
2021 Q3	19.4M	$14.5B	+$60.8M	53.6M	76.2M	$745.95	500
2021 Q2	19.4M	$12.5B	-$120M	77.2M	39.4M	$644.29	496
2021 Q1	19.6M	$11.2B	-$8.88M	14.2M	22.5M	$571.17	483
2020 Q4	19.7M	$11.4B	+$302M	15.4M	13.1M	$582.94	483
2020 Q3	19.3M	$9.93B	+$28.2M	14.7M	8.92M	$515.46	471
2020 Q2	19.2M	$8.67B	+$211M	10.5M	11.2M	$451.49	461
2020 Q1	18.8M	$6.6B	-$18.3M	12.7M	6.44M	$350.56	400
2019 Q4	18.9M	$6.99B	-$73.8M	8.81M	26.2M	$370.03	378
2019 Q3	19.2M	$6.4B	+$148M	27.6M	8.22M	$332.74	349
2019 Q2	18.7M	$5.84B	-$162M	4.85M	17M	$312.59	326
2019 Q1	19.4M	$5.94B	+$26.5M	64.2M	60.9M	$305.68	340
2018 Q4	19.1M	$4.43B	-$63.7M	7.92M	4.9M	$232.22	319
2018 Q3	18.9M	$5.92B	+$12.1M	3.26M	407K	$312.99	336
2018 Q2	19.1M	$5.51B	-$50.9M	2.28M	2.42M	$288.54	321
2018 Q1	19.3M	$4.82B	+$32.4M	4.98M	3.08M	$250.08	310
2017 Q4	19.2M	$4.58B	+$7.41M	8.14M	2.1M	$238.67	297
2017 Q3	19.2M	$4.26B	+$85M	1.29M	2.8M	$222.22	268
2017 Q2	18.8M	$4.26B	-$40.5M	1.04M	1.11M	$226.31	274
2017 Q1	19M	$3.8B	+$213M	99.6M	638K	$199.34	270
2016 Q4	19.7M	$3.6B	+$105M	729K	6.34M	$182.28	255
2016 Q3	19.1M	$3.13B	+$688K	864K	5.99M	$163.81	235
2016 Q2	19.1M	$2.73B	+$70.4M	57K	2.85M	$143.02	233
2016 Q1	18.6M	$2.54B	-$28.7M	697K	6.02M	$136.72	227
2015 Q4	18.8M	$2.61B	-$16.6M	347K	1.19M	$138.66	237
2015 Q3	18.8M	$2.53B	+$40.7M	363K	1.55M	$134.31	241
2015 Q2	18.7M	$2.81B	-$21.7M	934K	2.68M	$150.61	221
2015 Q1	18.9M	$2.55B	+$11.4M		2.29M	$135.18	216
2014 Q4	18.8M	$2.27B	+$17.6M		591K	$120.56	213
2014 Q3	18.6M	$2.11B	+$35.5M	0	1.01M	$113.40	198
2014 Q2	18.3M	$2.19B	+$17.8M	227K	1.8M	$119.71	201
2014 Q1	18.1M	$2.32B	-$19.6M	410K	602K	$128.12	189